FDA Advisory Panel To Discuss Vaccines Made From Human Tumor Cell Lines
This article was originally published in The Pink Sheet Daily
The Sept. 19 meeting of FDA’s Vaccines and Related Biological Products Advisory Committee comes as several whole-cell cancer vaccines are in Phase III trials.
You may also be interested in...
No longer the odd cousins of traditional pharmaceutical applications, a host of therapeutic cancer vaccines is working through late-stage trials with real, life-extending data already reported and the potential to create a lot of action in the oncology sector.
Problems that led to the capsizing of Dendreon Corp.’s Provenge prostate cancer immunotherapy are particular to the company and product, some cancer vaccine makers are quick to say. Nevertheless, what the Street saw as a commercial disaster for the pioneering treatment bears lessons for those who follow in the budding space.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.